Skip to content
Study details
Enrolling now

A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia

Novo Nordisk A/S
NCT IDNCT06859073ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

60

Study length

about 1.5 years

Ages

35–75

Locations

2 sites in CA, MD

About this study

Researchers are testing a new medicine called NNC4004-0002 to see if it's safe when given to people with high uric acid levels who don't have any symptoms. The trial will involve giving participants either the medicine or a placebo (a harmless substance) by injection under their skin. Participants will be asked to visit the clinic for several appointments and may need to stay overnight at the clinic for one of these visits.

Based on ClinicalTrials.gov records.

What participants do

  • 1.Take NNC4004-0002
  • 2.Take Placebo
PhasePhase 1
Primary goalNumber of Treatment-emergent adverse event (TEAEs)

Participation effort

Estimated from trial records. Details can vary by site.

Time + visits
Low10%
Logistics
Moderate50%

Logistics difficulty varies by site location and availability.

Trial highlights

Treatment details

Auto-extracted from trial records to preview treatments and outcomes.

Endpoints

Primary: Number of Treatment-emergent adverse event (TEAEs)

Secondary: AUC(0-72): The area under the NNC4004-0002 plasma concentration-time curve from time zero to the 72 hours after a single dose, Cmax: The maximum concentration of NNC4004-0002 in plasma, Renal clearance, tmax: The time from dose administration to the maximum plasma concentration of NNC4004-0002